ZIOPHARM announces expansion of ground-breaking synthetic immuno-oncology programs
ZIOPHARM announced expansion of synthetic immuno-oncology programs in conjunction with Intrexon to include chimeric antigen receptor T-cell therapy. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints. July 22, 2014